Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Medidata Announces Launch of Medidata Detect, Its Centralized Statistical Monitoring Solution for Clinical Trials

Medidata, a Dassault Systèmes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices. Medidata Detect, part of Medidata’s industry-leading, regulatory-compliant and unified Medidata Rave Clinical Cloud platform, helps customers manage data quality, monitor site performance, and promote patient safety by uncovering and finding errors, trends and anomalies in data through statistical algorithms and tests.

“Medidata Detect is a new and vital machine learning tool designed to improve data integrity and reduce trial risk,” said Glen de Vries, co-founder and co-CEO, Medidata. “Detect is another example of our continuous innovation that helps advance clinical trials with increased data accuracy and speed. It’s another way we’re working to get important new vaccines and therapeutics to patients in safer, faster ways.”

Recommended AI News: Dreamscape Media Inks Exclusive Audio and Video Partnership With Levine Querido

A report in the Journal of the American Medical Society (JAMA) found almost a quarter of new drug submissions required one or more resubmissions before they were approved, with a median delay to approval of 435 days following the first unsuccessful submission. Medidata Detect uses one central system for aggregation and review of any number of data sources, flagging data errors, trends, and anomalies in real time. This translates into better quality data and decisions throughout the trial, and shortens each cycle review time by weeks.

Recommended AI News: Magal Security Systems Wins $6.5 Million Contract to Secure Military Assets

Medidata Detect identifies known and unknown risks, and triggers corrective actions, which proactively minimize study delays and submission failures in trials. A foundational step in adopting a RBQM (risk-based quality management) approach to clinical development, Medidata Detect is able to define and manage study risks, expose unanticipated data anomalies and cut down on programmers’ time and effort through proprietary machine learning algorithms that require no customer programming.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

Recommended AI News: REELY Partners With PlayVS on Collegiate Summer Showdown

Leave A Reply

Your email address will not be published.